|
US5354902A
(en)
*
|
1992-10-26 |
1994-10-11 |
Mcneil-Ppc, Inc. |
Stabilized sorbic acid or salt thereof
|
|
ES2330202T5
(es)
|
2001-09-06 |
2014-01-20 |
Alphavax, Inc. |
Sistemas vectores basados en replicones de alfavirus
|
|
US7442381B2
(en)
|
2003-03-20 |
2008-10-28 |
Alphavax, Inc. |
Alphavirus replicons and helper constructs
|
|
CN1989250B
(zh)
|
2004-05-18 |
2013-11-20 |
阿尔法瓦克斯公司 |
Tc-83衍生的甲病毒属载体、颗粒和方法
|
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
|
US7332322B2
(en)
|
2004-09-14 |
2008-02-19 |
Ilya Frolov |
Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
|
|
KR101499750B1
(ko)
|
2006-02-27 |
2015-03-06 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
가감염성 플라비바이러스 및 이들의 용도
|
|
US8304529B2
(en)
|
2006-07-28 |
2012-11-06 |
Life Technologies Corporation |
Dinucleotide MRNA cap analogs
|
|
WO2009058911A2
(en)
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
|
AU2008338803B2
(en)
|
2007-11-26 |
2015-02-05 |
Glaxosmithkline Biologicals S.A. |
Methods of generating alphavirus particles
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
BRPI0913045A2
(pt)
|
2008-05-23 |
2017-05-23 |
Fit Biotech Oy |
vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
CN111808084A
(zh)
|
2008-11-10 |
2020-10-23 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
ES2647662T3
(es)
|
2009-12-31 |
2017-12-26 |
Medigen, Inc. |
Vacunas de ADN infeccioso frente al virus chikungunya
|
|
KR20190039347A
(ko)
|
2010-06-03 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
활성제의 전달을 위한 생분해성 지질
|
|
MX342608B
(es)
|
2010-07-06 |
2016-10-06 |
Novartis Ag * |
Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
NZ606591A
(en)
|
2010-07-06 |
2015-02-27 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
SI4043040T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
|
MX350258B
(es)
|
2011-07-06 |
2017-08-31 |
Novartis Ag |
Emulsiones cationicas de aceite en agua.
|
|
EP4115875A1
(en)
|
2011-07-06 |
2023-01-11 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
MX366055B
(es)
|
2011-08-31 |
2019-06-26 |
Novartis Ag |
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
|
|
EP3485875A1
(en)
*
|
2011-11-04 |
2019-05-22 |
Nitto Denko Corporation |
Single use system for sterelily producing lipid-nucleic acid particles
|
|
US9579338B2
(en)
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
EP3560486A1
(en)
|
2011-12-14 |
2019-10-30 |
Abraxis BioScience, LLC |
Use of polymeric excipients for lyophilization or freezing of particles
|
|
EP2852380A4
(en)
*
|
2012-05-23 |
2016-01-20 |
Univ Ohio State |
LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
|
|
EP2671591B1
(en)
|
2012-06-08 |
2017-08-09 |
Corden Pharma Brussels |
Process for the preparation of short-chain peptide powders
|
|
US8961995B2
(en)
|
2012-09-20 |
2015-02-24 |
Uab Research Foundation |
Methods and compositions for alphavirus replicons
|
|
WO2014170493A2
(en)
|
2013-04-19 |
2014-10-23 |
Novartis Ag |
Alphavirus vector
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
JP6506749B2
(ja)
|
2013-10-22 |
2019-04-24 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
フェニルケトン尿症のためのｍＲＮＡ療法
|
|
EP3798229A1
(en)
|
2014-03-25 |
2021-03-31 |
Yale University |
Uses of parasite macrophage migration inhibitory factors
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
EP4026568A1
(en)
*
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
|
HUE053990T2
(hu)
*
|
2015-07-22 |
2021-08-30 |
Nitto Denko Corp |
Nanorészecske liofilizált formák készítményei és eljárások
|
|
CN120842296A
(zh)
|
2015-09-21 |
2025-10-28 |
垂林克生物技术有限公司 |
用于合成5’-加帽rna的组合物和方法
|
|
AU2016354102B2
(en)
|
2015-11-09 |
2022-05-12 |
Immune Design Corp. |
A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017218704A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
WO2018010815A1
(en)
|
2016-07-15 |
2018-01-18 |
Biontech Rna Pharmaceuticals Gmbh |
Formulation for administration of rna
|
|
KR102718353B1
(ko)
|
2016-10-17 |
2024-10-15 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 바이러스 레플리콘 시스템 및 그의 용도
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
CA3040337A1
(en)
|
2016-10-26 |
2018-05-03 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
JP2020500552A
(ja)
|
2016-11-23 |
2020-01-16 |
グリットストーン オンコロジー インコーポレイテッド |
新生抗原のウイルスによる送達方法
|
|
CA3045650A1
(en)
|
2016-12-05 |
2018-06-14 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for enhancing gene expression
|
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
WO2018156617A2
(en)
|
2017-02-22 |
2018-08-30 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of polymer / biomacromolecule conjugates
|
|
US11407800B2
(en)
|
2017-02-28 |
2022-08-09 |
Arcturus Therapeutics, Inc. |
Translatable molecules and synthesis thereof
|
|
EP3634449A4
(en)
|
2017-05-08 |
2021-03-17 |
Gritstone Oncology, Inc. |
ALPHAVIRUS NEOANTIGEN VECTORS
|
|
ES3039647T3
(en)
|
2017-05-31 |
2025-10-23 |
Arcturus Therapeutics Inc |
Synthesis and structure of high potency rna therapeutics
|
|
BR112019025224A2
(pt)
|
2017-05-31 |
2020-12-08 |
Ultragenyx Pharmaceutical Inc. |
Terapêutica para doença de armazenamento de glicogênio tipo iii
|
|
CN111163799A
(zh)
|
2017-07-28 |
2020-05-15 |
扬森疫苗与预防公司 |
用于异源repRNA免疫接种的方法和组合物
|
|
WO2019121513A1
(en)
|
2017-12-18 |
2019-06-27 |
Intervet International B.V. |
Swine influenza a virus vaccine
|
|
JP7494117B2
(ja)
|
2018-01-19 |
2024-06-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えレプリコン系を使用する免疫応答の誘導および増強
|
|
WO2020014654A1
(en)
|
2018-07-13 |
2020-01-16 |
The Trustees Of Indiana University |
Recombinant rotavirus expression system and recombinant rotaviruses
|
|
US12083174B2
(en)
|
2018-08-17 |
2024-09-10 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
WO2020146700A1
(en)
|
2019-01-10 |
2020-07-16 |
Massachusetts Institute Of Technology |
Lipid nanoparticles
|
|
SG11202110036RA
(en)
|
2019-03-19 |
2021-10-28 |
Arcturus Therapeutics Inc |
Method of making lipid-encapsulated rna nanoparticles
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
GB201908729D0
(en)
|
2019-06-18 |
2019-07-31 |
Imp College Innovations Ltd |
RNA construct
|
|
AU2020298267A1
(en)
|
2019-06-20 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof
|
|
DK4037708T3
(da)
|
2019-09-30 |
2024-09-30 |
Gilead Sciences Inc |
HBV-vacciner og fremgangsmåder til at behandle HBV
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US12351834B2
(en)
|
2020-03-03 |
2025-07-08 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
AU2021236068A1
(en)
|
2020-03-09 |
2022-10-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
|
TW202313967A
(zh)
|
2021-07-30 |
2023-04-01 |
美商亞克圖羅斯醫療公司 |
Ｒｎａ疫苗
|